Results 311 to 320 of about 1,506,204 (342)
Some of the next articles are maybe not open access.
Molecular and Cellular Biochemistry, 1984
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
S P, Cole +4 more
openaire +2 more sources
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
S P, Cole +4 more
openaire +2 more sources
2001
Publisher Summary Monoclonal antibody therapy (MAT) makes use of all the major features of the immune response. It involves vaccination/ immunization, albeit in experimental animals, to induce the desired specific immune response. It exploits the high specificity, selectivity, and affinity of the antibody complementarity-determining regions (CDRs ...
J W, Park, J, Smolen
openaire +2 more sources
Publisher Summary Monoclonal antibody therapy (MAT) makes use of all the major features of the immune response. It involves vaccination/ immunization, albeit in experimental animals, to induce the desired specific immune response. It exploits the high specificity, selectivity, and affinity of the antibody complementarity-determining regions (CDRs ...
J W, Park, J, Smolen
openaire +2 more sources
ANTIRETINOBLASTOMA MONOCLONAL ANTIBODIES
Retina, 1983Mouse-mouse somatic hybridization techniques were used to produce monoclonal antibodies directed towards antigen expressed on retinoblastoma-derived tissue culture cell lines. Four monoclonal antibodies were produced with varying avidity which were reactive against allogeneic retinoblastoma-associated antigens.
D H, Char +4 more
openaire +2 more sources
Multispecific monoclonal antibodies
Immunology Today, 1986Monoclonal antibodies are frequently shown to participate in unexpected cross reactions involving two apparently dissimilar antigens. This can be attributed either to partial epitope identity or to irrelevant interactions involving additional binding capacity of the antibody.
S, Ghosh, A M, Campbell
openaire +2 more sources
2009
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
THERAPEUTIC MONOCLONAL ANTIBODIES
Rheumatology, 1995Monoclonal antibodies have been used extensively over the last few years in clinical trials of rheumatoid arthritis (RA). Not only are they potential therapeutic agents, but they are also useful probes into the immunopathogenesis of RA. Anti-tumour necrosis factor alpha (TNF alpha) monoclonal antibodies have been shown to be clinically efficacious ...
E H, Choy, G S, Panayi, G H, Kingsley
openaire +2 more sources
Monoclonal antibody biosimilars
Nature Reviews Drug Discovery, 2015With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics.
Natasha, Udpa, Ryan P, Million
openaire +2 more sources
Therapeutic monoclonal antibodies
The Lancet, 2000The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being ...
openaire +2 more sources
Recombinant Monoclonal Antibodies
2007Recombinant antibody technology is a rapidly evolving field that enables the study and improvement of antibody properties by means of genetic engineering. Moreover, the functional expression of antibody fragments in Escherichia coli has formed the basis for antibody library generation and selection, a powerful method to produce human antibodies for ...
Mariel, Donzeau, Achim, Knappik
openaire +2 more sources